Akazawa K, Kamakura T, Sakamoto M, Odaka T, Nose Y
Department of Medical Informatics, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Methods Inf Med. 1994 Dec;33(5):530-4.
This article describes the design and results of implementation of an automated patient registration and treatment allocation system (RETAS) used in multicenter clinical trials. RETAS was developed using a FAX-OCR system by which handwritten Japanese and English characters, as well as numericals and forms with check boxes, are sent from participating institutions by Fax, processed using an optical character reader, and then transmitted to a host computer at a statistical center. Based on the facsimile data, RETAS can automatically review eligibility, collect patient identification data and provide a randomized treatment allocation. RETAS permits uninterrupted, unattended operation at a statistical center, 24 hours a day, 7 days a week. Therefore, it drastically decreases the workload of personnel at the statistical center needed to support central telephone registration coverage. Consequently, staff members are free to focus on patient registration, treatment allocation, and follow-up of patients. The treatment allocation procedure in this system is based on Pocock and Simon's minimization method combined with Zelen's method for institution balancing. By this system it was possible to balance treatment numbers for each level of various prognostic factors over an entire trial and, at the same time, balance the allocation of treatments within an institution. The system currently supports the protocol of a clinical trial for Adjuvant Chemo-Endocrine Therapy for Breast Cancer in West Japan.
本文介绍了一种用于多中心临床试验的自动化患者登记与治疗分配系统(RETAS)的设计及实施结果。RETAS是利用传真光学字符识别(FAX - OCR)系统开发的,参与机构通过传真发送手写的日文和英文文字、数字以及带有复选框的表格,这些内容经光学字符阅读器处理后传输至统计中心的主机。基于传真数据,RETAS能够自动审核合格性、收集患者识别数据并提供随机治疗分配。RETAS允许统计中心每周7天、每天24小时进行不间断无人值守操作。因此,它大幅减少了支持中央电话登记覆盖所需的统计中心人员的工作量。结果,工作人员能够自由地专注于患者登记、治疗分配以及患者随访。该系统中的治疗分配程序基于波科克和西蒙的最小化方法,并结合泽伦的机构平衡方法。通过该系统,可以在整个试验中平衡各预后因素不同水平的治疗人数,同时平衡机构内的治疗分配。该系统目前支持日本西部乳腺癌辅助化疗 - 内分泌治疗临床试验的方案。